Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, estudio No reclutando aún

Not Yet Recruiting

ID del estudio CA061-1011  |   NCT07015983

A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Ícono de advertencia
Lo sentimos, este estudio aún no acepta participantes.
Marque esta página como favorita para volver a consultarla en una fecha posterior.  También puede hacer clic en el botón “Verificar su elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad

Resumen

  • Phase 2
  • Ícono de género masculino y femenino
  • 16+
  • 49
  • Ícono de BMS, estudio No reclutando aún
    Not Yet Recruiting

Descripción general

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Key

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must meet EULAR/ACR 2019 criteria for SLE.
    1. Participants must have an inadequate response to appropriate doses of glucocorticoids and ≥ 2 immunosuppressant therapies, used for at least 3 months.
      1. Participants must have active disease when signing ICF. Key

        Criterios de exclusión

        Criterios de exclusión Icon
        :
        • Participants must not have other diseases, conditions, or treatments that may confound interpretation of the effects of CC-97540 in SLE.
          1. Uncontrolled or clinically significant cardiovascular conditions or CNS pathology participants must not have prior history of malignancies or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years, except for some non-invasive malignancies.
            1. IOCBP who are pregnant, nursing, or breastfeeding, or who intend to become pregnant during participation in the study.
              1. Participants must not have prior treatment with CAR T cell therapy, genetically modified T cell therapy, or stem cell transplant. Washout periods may be required.
                1. Participants must not have received live vaccines within 6 weeks before CC-97540 administration.
                  1. Participant must not have inadequate organ function.
                    1. Other protocol defined inclusion/exclusion criteria apply.
                      Información Adicional *

                      Opciones de tratamiento

                      Brazos del estudio

                      INTERVENCIÓN ASIGNADA

                      Brazos del estudio

                      Experimental: Administration of CC-97540

                      INTERVENCIÓN ASIGNADA
                      • Drug: CC-97540, Fludarabine, Cyclophosphamide
                      Vuelva a consultar más tarde para encontrar un sitio de reclutamiento o encuentre otro estudio haciendo clic en “Verificar su elegibilidad”
                      Verifique su elegibilidad
                      Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                      Compatibilizar con un estudio
                      Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                      Seleccione una ubicación del centro del estudio
                      Seleccione una ubicación del centro del estudio que sea conveniente para usted
                      Registrarse
                      Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                      Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias